iLoF: AI-augmented photonics to identify and quantify disease biomarkersbroad
iLoF · Horizon Europe grant · 2023-08-01–2025-07-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery & development. Through advanced AI & photonics, we collect massive amounts of data to build a digital library of biomarkers & biological profiles, bringing together world-class physicists, biologists, & data scientists to get life-saving personalized treatments to patients faster. Our platform captures label-free patterns in biological liquid samples, to generate specific patient or disease signatures. The iLoF device generates multiple highly focused, non-destructive laser beams that interrogate the biological sample to obtain a digital signal of its light pattern. That signal is used to detect modifications providing a flexible & agnostic tool that is not limited to a single use or disease. The current project focuses on developing an Alzheimers disease (AD) clinical trial patient screening tool.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ILOF - INTELLIGENT LAB ON FIBER, UNIPESSOAL LDA | PT | coordinator | €2,495,850 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.